© 2025 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY
WEDW-FM · WNPR · WPKT · WRLI-FM
Public Files Contact · ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

France Bars Use Of Hydroxychloroquine In COVID-19 Cases

The move comes after the World Health Organization halted clinical trials of the drug as a treatment, citing a study that found no benefit and a higher mortality rate for hospitalized patients. A box of hydroxychloroquine, under the brand name Plaquenil, is seen in a pharmacy in Paris.
Chesnot
/
Getty Images
The move comes after the World Health Organization halted clinical trials of the drug as a treatment, citing a study that found no benefit and a higher mortality rate for hospitalized patients. A box of hydroxychloroquine, under the brand name Plaquenil, is seen in a pharmacy in Paris.

The French government is revoking a decree that had allowed hospitals to prescribe hydroxychloroquine in some COVID-19 cases, saying there is no proof that it helps patients — and citing data that shows it could cause heart problems and other health risks.

"This molecule must not be prescribed for patients affected by COVID-19," the Ministry of Solidarity and Health said as it announced the change.

The move to bar hospitals from prescribing the drug for coronavirus patients comes two days after the World Health Organization halted clinical trials of hydroxychloroquine as a treatment for COVID-19. The WHO cited a study published in The Lancet, that had found no benefit from the drug and reported a higher mortality rate for hospitalized patients and "an increased frequency of ventricular arrhythmias."

France's health ministry had approved hydroxychloroquine for emergency prescriptions in COVID-19 cases in late March.

As France 24 reports, that's when French researcher Didier Raoult, who has been an insistent proponent of hydroxychloroquine, said he had successfully treated COVID-19 patients using the controversial drug in combination with azithromycin. But the health ministry says recent studies show the treatment can produce "cardiac toxicity, particularly in combination with azithromycin."

Researchers continue to evaluate the possible use of hydroxychloroquine, which is used to treat malaria and lupus, to fight the coronavirus, with at least two studies underway in the U.S. As NPR's Joe Palca reports, the drug has been found to be able to prevent replication of the coronavirus.

President Trump has frequently touted hydroxychloroquine as a treatment for COVID-19 — and last week, he said that he was taking doses of both hydroxychloroquine and zinc to protect against the coronavirus, despite warnings about the drug.

"I've taken it for about a week and a half now. And I'm still here," he said.

Both the Food and Drug Administration and the National Institutes of Health have warned of health risks involved with people taking hydroxychloroquine hoping to prevent or treat COVID-19.

On the same day Trump said he was taking the drug, the FDA issued a list of its potentially dangerous side effects:

"Side effects of hydroxychloroquine include irreversible retinal damage, cardiac effects (including cardiomyopathy and QT prolongation), worsening of psoriasis and porphyria, proximal myopathy and neuropathy, neuropsychiatric events, and hypoglycemia."

Copyright 2021 NPR. To see more, visit https://www.npr.org.

Bill Chappell is a writer and editor on the News Desk in the heart of NPR's newsroom in Washington, D.C.

The independent journalism and non-commercial programming you rely on every day is in danger.

If you’re reading this, you believe in trusted journalism and in learning without paywalls. You value access to educational content kids love and enriching cultural programming.

Now all of that is at risk.

Federal funding for public media is under threat and if it goes, the impact to our communities will be devastating.

Together, we can defend it. It’s time to protect what matters.

Your voice has protected public media before. Now, it’s needed again. Learn how you can protect the news and programming you depend on.

SOMOS CONNECTICUT is an initiative from Connecticut Public, the state’s local NPR and PBS station, to elevate Latino stories and expand programming that uplifts and informs our Latino communities. Visit CTPublic.org/latino for more stories and resources. For updates, sign up for the SOMOS CONNECTICUT newsletter at ctpublic.org/newsletters.

SOMOS CONNECTICUT es una iniciativa de Connecticut Public, la emisora local de NPR y PBS del estado, que busca elevar nuestras historias latinas y expandir programación que alza y informa nuestras comunidades latinas locales. Visita CTPublic.org/latino para más reportajes y recursos. Para noticias, suscríbase a nuestro boletín informativo en ctpublic.org/newsletters.

The independent journalism and non-commercial programming you rely on every day is in danger.

If you’re reading this, you believe in trusted journalism and in learning without paywalls. You value access to educational content kids love and enriching cultural programming.

Now all of that is at risk.

Federal funding for public media is under threat and if it goes, the impact to our communities will be devastating.

Together, we can defend it. It’s time to protect what matters.

Your voice has protected public media before. Now, it’s needed again. Learn how you can protect the news and programming you depend on.

Related Content